A fellow Synovial Sarcoma caregiver told me about Reolysin. It's a pretty interesting drug. It's a live virus that doesn't do a lot of harm to normal cells. The basic idea is that cancer cells are deficient in their ability to combat this virus, whereas normal cells are not. Thus, the virus multiplies rapidly in cancer cells, eventually killing them. The good thing about it is it claims to have very little side effects.
It's some type of nano-particle gene delivery molecule that targets metastatic cancers in general. It also claims to target primary tumors. It's currently in clinical trials for the following cancers:
Soft tissue sarcomas (STS) aren't very common as far as cancers go. They make up about less than 1% of all new cancer cases in the US each year. As a result, much less attention and fewer resources have been directed towards finding cures or palliative treatments for them. The standard of conventional chemotherapy is currently Doxorubicin and Ifosfamide.
Deforolimus is another newer drug for addressing Soft Tissue Sarcomas (STS). Aside from ET-743 (Yondelis), there are few alternatives out there since soft tissue sarcoma cases are a minority (<1% new of all new cancer cases in the US) and there is not as much financial incentive to find cures for it compared to the other more common cancers.
Soft tissue sarcomas (STS) aren't very common as far as cancers go. They make up about less than 1% of all new cancer cases in the US each year. As a result, much less attention and fewer resources have been directed towards finding cures or palliative treatments for them. The standard of conventional chemotherapy is currently Doxorubicin and Ifosfamide.
